| Dr Melvin Delaine Thornbury Jr, MD | |
|
431 N Carlisle St, Suite 220, Albertville, AL 35950-1733 | |
| (256) 840-4520 | |
| (256) 840-4527 |
| Full Name | Dr Melvin Delaine Thornbury Jr |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 36 Years |
| Location | 431 N Carlisle St, Albertville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386683902 | NPI | - | NPPES |
| 51550422 | Medicaid | AL | |
| 51550422 | Other | AL | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 14828 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marshall Medical Centers | Boaz, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Melvin D Thornbury Jr Md Pc | 8628242344 | 3 |
News Archive
Next Generation Sequencers have found their way into service providing labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Disparities in breast cancer mortality continue to be unacceptably high in Chicago and significantly larger than the national average according to new data released today at a rally sponsored by the Metropolitan Chicago Breast Cancer Task Force. The Task Force also announced results of the first year of data collection by the Chicago Breast Cancer Quality Consortium, which found many hospitals in Chicago are not meeting accepted quality standards.
Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.
David Julian McClements, Distinguished Professor of Food Science at the University of Massachusetts Amherst and among the world's most highly cited researchers, has written a new book that explores the brave new world of science and food.
› Verified 2 days ago
| Entity Name | Melvin D Thornbury Jr Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740567486 PECOS PAC ID: 8628242344 Enrollment ID: O20111115000540 |
News Archive
Next Generation Sequencers have found their way into service providing labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Disparities in breast cancer mortality continue to be unacceptably high in Chicago and significantly larger than the national average according to new data released today at a rally sponsored by the Metropolitan Chicago Breast Cancer Task Force. The Task Force also announced results of the first year of data collection by the Chicago Breast Cancer Quality Consortium, which found many hospitals in Chicago are not meeting accepted quality standards.
Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.
David Julian McClements, Distinguished Professor of Food Science at the University of Massachusetts Amherst and among the world's most highly cited researchers, has written a new book that explores the brave new world of science and food.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Melvin Delaine Thornbury Jr, MD 415 Martling Rd, Albertville, AL 35951-7209 Ph: (256) 660-5560 | Dr Melvin Delaine Thornbury Jr, MD 431 N Carlisle St, Suite 220, Albertville, AL 35950-1733 Ph: (256) 840-4520 |
News Archive
Next Generation Sequencers have found their way into service providing labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool.
InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
Disparities in breast cancer mortality continue to be unacceptably high in Chicago and significantly larger than the national average according to new data released today at a rally sponsored by the Metropolitan Chicago Breast Cancer Task Force. The Task Force also announced results of the first year of data collection by the Chicago Breast Cancer Quality Consortium, which found many hospitals in Chicago are not meeting accepted quality standards.
Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.
David Julian McClements, Distinguished Professor of Food Science at the University of Massachusetts Amherst and among the world's most highly cited researchers, has written a new book that explores the brave new world of science and food.
› Verified 2 days ago